Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Capital Leases (2016 - 2017)

Neurocrine Biosciences (NBIX) has disclosed Capital Leases for 8 consecutive years, with $544000.0 as the latest value for Q1 2017.

  • For the quarter ending Q1 2017, Capital Leases fell 32.76% year-over-year to $544000.0, compared with a TTM value of $544000.0 through Mar 2017, down 32.76%, and an annual FY2016 reading of $617000.0, down 60.32% over the prior year.
  • Capital Leases was $544000.0 for Q1 2017 at Neurocrine Biosciences, down from $617000.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $3.0 million in Q1 2013 and bottomed at $544000.0 in Q1 2017.
  • Average Capital Leases over 5 years is $1.8 million, with a median of $2.1 million recorded in 2015.
  • The sharpest move saw Capital Leases skyrocketed 32.63% in 2013, then plummeted 61.22% in 2016.
  • Year by year, Capital Leases stood at $2.7 million in 2013, then fell by 17.5% to $2.2 million in 2014, then decreased by 29.67% to $1.6 million in 2015, then plummeted by 60.32% to $617000.0 in 2016, then dropped by 11.83% to $544000.0 in 2017.
  • Business Quant data shows Capital Leases for NBIX at $544000.0 in Q1 2017, $617000.0 in Q4 2016, and $649000.0 in Q3 2016.